HF  Janus Henderson Investors

https://www.janushenderson.com/





     Office Locations:

151 Detroit Street
Denver, CO 80206
Phone: 800-525 3713

Get all office locations for this firm with a National Database subscription or Southern California Database subscription.
 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Janus Henderson (NYSE: JHG) is a global asset manager with more than 345 investment professionals and expertise across all major asset classes. The firm's individual, intermediary and institutional clients span the globe and entrust us with more than POUND277.1bn of their assets. Janus Henderson Multi-Asset includes teams in the US and UK. The US-based teams manage US and global asset allocation strategies. The UK-based team has asset allocation specialists, traditional multi-manager investors and those focused on alternative asset classes. The team has 90 years of investment experience.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Southern California Database subscription.
    Dick Weil CEO

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      10/23/2024


      Alpha-9 Oncology


      MA


      $175,000,000


      Series C


      10/17/2024


      Aktis Oncology


      MA


      $175,000,000


      Series B


      07/23/2024


      Third Arc Bio


      MA


      $165,000,000


      Series A


      04/03/2024


      Obsidian Therapeutics


      MA


      $160,500,000


      Series C


      02/13/2024


      ProfoundBio


      WA


      $112,000,000


      Series B


      12/14/2023


      Parse Biosciences


      WA


      $50,000,000


      Series C


     

    Portfolio companies include:


      4D Molecular Therapeutics
        web link


      Akero Therapeutics
        web link


      Aktis Oncology
        web link


      Alpha-9 Oncology
        web link


      Amunix
        web link


      Annexon Biosciences
        web link


      Artiva Biotherapeutics
        web link


      Athira Pharma
        web link


      Bicara Therapeutics
        web link


      Bigfoot Biomedical
        web link


      BioAtla
        web link


      Black Diamond Therapeutics


      CARGO Therapeutics
        web link


      Caribou Biosciences
        web link


      Cedilla Therapeutics
        web link


      Centessa Pharmaceuticals
        web link


      Ceptur Therapeutics
        web link


      Chroma Medicine
        web link


      Cyteir Therapeutics
        web link


      Day One Biopharmaceuticals
        web link


      Decibel Therapeutics
        web link


      Disc Medicine
        web link


      Elevation Oncology
        web link


      Forma Therapeutics
        web link


      Freenome


      HeartFlow
        web link


      Icosavax


      IGM Biosciences
        web link


      iTeos Therapeutics
        web link


      Janux Therapeutics
        web link


      Kinnate Biopharma
        web link


      Kymera Therapeutics
        web link


      Loadsmart
        web link


      Magic Leap


      Neurogene
        web link


      Obsidian Therapeutics
        web link


      Olema Oncology
        web link


      Parse Biosciences
        web link


      ProfoundBio
        web link


      Pyxis Oncology


      Shattuck Labs


      ShouTi
        web link


      Sonoma Biotherapeutics
        web link


      Stoke Therapeutics
        web link


      SutroVax
        web link


      Third Arc Bio
        web link


      VelosBio
        web link


      Verve Therapeutics
        web link


      VIA


     

    Recent News: